The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Randomized phase II study comparing the MET inhibitor cabozantinib to temozolomide (TMZ) or dacarbazine (DTIC) in ocular melanoma: A091201.
 
Jason John Luke
Honoraria - Intellisphere, LLC
Consulting or Advisory Role - Amgen; Bayer; Genentech
Research Funding - EMD Serono; GlaxoSmithKline; Novartis
Travel, Accommodations, Expenses - Amgen; Bayer; Bristol-Myers Squibb; Genentech
 
Jacob B Allred
No Relationships to Disclose
 
Laura E. Horvath
No Relationships to Disclose
 
Bruno R. Bastos
Consulting or Advisory Role - Boehringer Ingelheim
 
Charles Erlichman
No Relationships to Disclose
 
Gary K. Schwartz
Honoraria - AstraZeneca; Boehringer Ingelheim; Novartis
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Novartis
Patents, Royalties, Other Intellectual Property - Patent pending regarding development of PNAs for targeted cancer therapy (new technology)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Novartis